Is tirzepatide better than semaglutide? On the available head-to-head data, tirzepatide produces larger A1C and weight reductions, especially at higher doses, but the answer depends on which outcome you weigh, how you tolerate side effects, and what your insurance covers. Both medications work; the right choice is patient-specific.
What These Two Drugs Are
Semaglutide is a pure GLP-1 receptor agonist sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both are once-weekly injections, both are made by major manufacturers (Novo Nordisk and Eli Lilly respectively), and both have been the subject of extensive randomized trials.
SURPASS-2: The Head-to-Head Trial
The most-cited direct comparison is SURPASS-2, published in the New England Journal of Medicine in 2021. The 40-week trial randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin to weekly tirzepatide (5, 10, or 15 mg) or weekly semaglutide 1 mg.
A1C Results
Mean A1C reductions from baseline:
- Tirzepatide 5 mg: -2.01%
- Tirzepatide 10 mg: -2.24%
- Tirzepatide 15 mg: -2.30%
- Semaglutide 1 mg: -1.86%
All three tirzepatide doses produced statistically significant greater A1C reductions than semaglutide 1 mg.
Weight Results
Mean weight reductions from baseline:
- Tirzepatide 5 mg: -7.6 kg
- Tirzepatide 10 mg: -9.3 kg
- Tirzepatide 15 mg: -11.2 kg
- Semaglutide 1 mg: -5.7 kg
Important Caveats When Comparing the Two
SURPASS-2 used semaglutide at the 1 mg dose approved at the time for type 2 diabetes. The current weight-management dose of semaglutide is 2.4 mg, and direct head-to-head data against that higher dose is limited. Indirect comparisons (STEP 1 versus SURMOUNT-1) suggest tirzepatide still produces larger average weight loss, but differences may narrow.
The ongoing SURMOUNT-5 trial directly compares tirzepatide and semaglutide 2.4 mg in obesity. Initial results published in 2025 reported that tirzepatide produced significantly greater weight loss than semaglutide 2.4 mg over 72 weeks, though both produced clinically meaningful reductions.
| Outcome | Tirzepatide 15 mg | Semaglutide 1 mg (SURPASS-2) | Semaglutide 2.4 mg (STEP 1) |
|---|---|---|---|
| A1C reduction (T2D) | -2.30% | -1.86% | Not labeled for T2D |
| Weight loss (T2D / obesity) | -11.2 kg / up to -20.9% | -5.7 kg | -14.9% |
| Common GI side effects | Nausea, diarrhea | Nausea, diarrhea | Nausea, diarrhea |
Side Effects and Tolerability
The side-effect profiles are broadly similar. Both cause GI symptoms (nausea, vomiting, diarrhea, constipation) during dose escalation. SURPASS-2 found mild-to-moderate GI events slightly more common with tirzepatide, but discontinuation rates were comparable. Both carry FDA boxed warnings for thyroid C-cell tumors based on rodent data, and both are contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis and gallbladder disease are listed warnings for both.
Dosing and Titration
Both drugs start low and titrate up to balance efficacy and tolerability.
- Semaglutide (Wegovy): 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, with each step lasting 4 weeks.
- Tirzepatide (Zepbound): 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg, with each step lasting at least 4 weeks.
Cost and Coverage Considerations
List prices are similar (roughly $1,000-$1,400 per month). Coverage varies by insurer, plan, and indication. Manufacturer savings cards from Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) can substantially reduce out-of-pocket cost for commercially insured patients but exclude government insurance. Cash pay options exist through Lilly Direct (Zepbound vials) and NovoCare (Wegovy direct pricing).
How to Decide With Your Clinician
Useful questions for the visit:
- What is the indication you are treating – T2D, obesity, OSA, or cardiovascular risk?
- Which medication does my insurance prefer?
- Do I have any contraindications such as personal or family history of MTC?
- How do my comorbidities (gallbladder, pancreatitis, gastroparesis) affect choice?
- What is the realistic out-of-pocket cost on each option?
For broader context on metabolic care, see our overviews of prediabetes treatment and the A1C test.
The Bottom Line
Is tirzepatide better than semaglutide? On head-to-head A1C and weight outcomes in SURPASS-2 and indirect obesity comparisons, tirzepatide produces larger average results. Side effects, dosing, contraindications, and especially cost and coverage often decide which is the better fit for an individual patient. Both are effective, evidence-based options when used appropriately.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.
